April 8, 2022
Letter to Califf calls attention to Menopause study
APC was one of four organizations — including APhA, NCPA, and PCCA — that sent a letter to FDA Commissioner Robert Califf making him aware of the peer-reviewed study in Menopause, the Journal of The North American Menopause Society, that we wrote about last week — the one that found no evidence that compounded hormones pose an increased clinical risk compared to FDA-approved products.
“As you continue to evaluate what, if any, additional steps the FDA will take in response to the National Academies of Science, Engineering, and Mathematics (NASEM) study,” the letter said, “we encourage you to keep these new findings in mind and help ensure continued access to these important therapies.”
A special thank you to PCCA for taking the lead on this message.
